Skip to main content

Table 5 Multivariable logistic regression analysis

From: Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

Variable

Overall CD34+ collection results (≥ 10 × 106/kg bw versus < 10)

CD34+ cells in PB ((≥ 50/µl versus < 50/µl)

Odds ratio

[95% CI]

p value

Odds ratio

[95% CI]

p value

Age (> 60 versus ≤ 60 years)

0.89

[0.45 -1.76]

0.743

0.68

[0.34 -1.38]

0.289

High-risk cytogenetic (yes versus no)

0.95

[0,41 -2.20]

0.904

1.14

[0.47 -2.80]

0.773

ISS (3 versus 1–2)

1.50

[0.72 -3.09]

0.279

1.07

[0.50 -2.30]

0.854

Induction 6 × RVd vs. other

0.88

[0.37 -2.09]

0.770

1.22

[0.49 -3.03]

0.671

Induction 6 × Isa-RVd vs. other

0.17

[0.05 -0.51]

0.002

1.53

[0.57 -4.07]

0.399

Induction 4 × Elo-RVd vs. other

1.24

[0.54 -2.88]

0.611

2.59

[0.97 -6.89]

0.057

Remission prior to mobilization

(≥ VGPR versus < VGPR)

1.39

[0.66 -2.90]

0.384

1.34

[0.62 -2.90]

0.460

Variable

LP delay (≥ 1 day versus 0 days)

LP sessions ((≥ 2 versus 1)

Odds ratio

[95% CI]

p value

Odds ratio

[95% CI]

p value

Age (> 60 versus ≤ 60 years)

1.71

[0.79 – 3.70]

0.172

1.03

[0.52 -2.04]

0.929

High-risk cytogenetic (yes versus no)

2.37

[0.98 -5.73]

0.055

0.80

[0.34 -1.87]

0.594

ISS (3 versus 1–2)

1.20

[0.51 -2.80]

0.677

1.55

[0.74 -3.26]

0.247

Induction 6 × RVd vs. other

1.72

[0.62 -4.72]

0.296

1.69

[0.69 -4.12]

0.252

Induction 6 × Isa-RVd vs. other

1.30

[0.43 -3.92]

0.646

2.47

[0.97 -6.30]

0.058

Induction 4 × Elo-RVd vs. other

0.80

[0.27 -2.41]

0.693

0.61

[0.24 -1.57]

0.305

Remission prior to mobilization

(≥ VGPR versus < VGPR)

0.76

[0.32 -1.78]

0.528

0.79

[0.38 -1.66]

0.531

  1. CI Confidence interval, Elo Elotuzumab, Isa Isatuximab, ISS International Staging System, LP Leukapheresis, PB Peripheral blood, RVd Lenalidomide, bortezomib, dexamethasone, VGPR Very good